非霍奇金淋巴瘤（NHL）.pdf

1、Saturday,March 1,2025ModeratorNeil Love,MDRahul Aggarwal,MDAditya Bardia,MD,MPHMitesh J Borad,MDVirginia F Borges,MD,MMScHarold J Burstein,MD,PhDRashmi Chugh,MDChristopher Flowers,MD,MSFacultyJonathan Goldman,MDNicole Lamanna,MDNatasha B Leighl,MD,MMSc Amit Mahipal,MD,MPH William K Oh,MD David M OMa

2、lley,MD Joyce OShaughnessy,MD Krish Patel,MDRichard F Riedel,MD Kerry A Rogers,MD Simron Singh,MD,MPHBrian M Slomovitz,MD Jonathan Strosberg,MD Module 8:Biliary Tract CancersTargeted Therapeutic Approaches for Patients with BTCs Dr MahipalIntegration of Immune Checkpoint Inhibitors into Current Bili

3、ary Tract Cancer(BTC)Management Dr BoradModule 8:Biliary Tract CancersTargeted Therapeutic Approaches for Patients with BTCs Dr MahipalIntegration of Immune Checkpoint Inhibitors into Current Biliary Tract Cancer(BTC)Management Dr BoradTargeted Therapeutic Approaches for Patients with BTCs Amit Mahi

4、pal,MBBS,MPHProfessorDirector GI OncologyUH Seidman Cancer CenterCase Western Reserve UniversityMarch 1,2025Part of aDisclosuresNo relevant conflicts of interest to discloseBackgroundAnnual incidence in US:12,190Overall incidence has increased progressively worldwide over the past four decades.Aggre

5、ssive disease with five-year overall survival rates for advanced stage disease females Risk factors:primary sclerosing cholangitis,gallstones,Lynch syndrome,Opisthorchis viverrini or Clonorchis sinensis,bile duct morphologic anomalies Typically presents with obstructive jaundiceBiliary Cancers11.Val

6、le JW et al.Cancer Discov.2017;7:943-962.Biliary cancers 90%of cases are adenocarcinoma Level 1 evidence for adjuvant chemotherapy:capecitabine Palliative first-line chemotherapy:cisplatin/gemcitabine No second-line palliative chemotherapy with a demonstrated survival benefit over active symptom con